California Supreme Court Clarifies Bounds of Legitimate Competition Under Tort and Antitrust Law
September, 2020 - Julian (Pete) Mack
On August 3, 2020, the California Supreme Court issued its highly anticipated decision in Ixchel Pharma, LLC v. Biogen, Inc., clarifying the bounds of legitimate competition under California tort and antitrust law. The Court’s ruling generally came down in favor of encouraging competition, reducing claims for tortious interference with contract, and decreasing the risk of litigation arising from normal competitive activity. There are two significant takeaways for California businesses from the Ixchel opinion: